Skip to main content

Table 1 Target coverage in the nominal and worst-case plans

From: Assessing the robustness of passive scattering proton therapy with regard to local recurrence in stage III non-small cell lung cancer: a secondary analysis of a phase II trial

  Vprescription dose(%) D95(Gy)
  To PTV (nominal plan) To CTV (worst-case) Difference To PTV (nominal plan) To CTV (worst-case) Difference
Patient 1 90.7 89.1 1.6 72.0 70.9 1.1
Patient 2 93.9 93.4 0.5 73.4 73.4 0
Patient 3 95.6 91.1 3.5 74.2 72.7 1.5
Patient 4 90.0 85.6 4.4 69.2 66.9 2.3
Patient 5 81.0 78.0 3.0 68.9 65.4 3.5
Patient 6 88.1 83.0 4.1 67.3 64.8 2.5
Patient 7 93.0 91.0 2.0 72.0 70.8 1.2
Patient 8 81.1 78.5 2.6 69.4 67 2.4
Patient 9§       
1st plan 95.1 93.1 2.0 44.0 43.6 0.4
2nd plan 97.6 93.6 4.0 30.3 29.8 0.5
  1. Abbreviations: V prescription dose volume (in percent) receiving at least the prescription dose, D 95 the minimum dose received by 95% of the target, PTV planning target volume, CTV clinical target volume.
  2. §Two plans were prepared for this patient during the radiation therapy (“adaptive planning”); the prescribed doses were 44 Gy in the first plans and 30 Gy in the second.